Regular Article
Expression of Cytochrome P450 2A6 in Escherichia coli: Purification, Spectral and Catalytic Characterization, and Preparation of Polyclonal Antibodies

https://doi.org/10.1006/abbi.1999.1388Get rights and content

Abstract

Cytochrome P450 (CYP) 2A6 is the principal human enzyme catalyzing coumarin 7-hydroxylation and is known to be involved in the metabolism of halothane, nicotine, and metabolic activation of butadiene and nitrosamines. In this paper expression of CYP2A6 in Escherichia coli is reported. In order to achieve expression, the N-terminus of protein was modified by PCR mutagenesis. The N-terminal variant with only a single amino acid change showed expression of 210 nmol of CYP2A6/liter of culture. Recombinant CYP2A6 protein was purified to electrophoretic homogeneity and further characterized. Absolute spectra were typical for CYP proteins and indicated low spin characteristics of isolated protein. Due to a hydrophobic segment the N-terminal amino acid sequence of recombinant CYP2A6 was blocked. The N-terminal formylmethionine block was removed by mild acid treatment. Purified CYP2A6 had good catalytic activity toward marker substrate coumarin in a reconstituted system (Km = 1.48 ± 0.37 μM, Vmax = 3.36 ± 0.18 nmol product/min/nmol CYP). Its activity in the reconstituted system was stimulated by the presence of cytochrome b5 and glutathione. CYP2A6 was shown to metabolize chlorzoxazone in the reconstituted system with activity of 0.32 nmol of product/min/nmol of CYP, and thus caution should be taken when interpretation of CYP2E1 in vivo phenotyping data is performed. Rabbit polyclonal antibodies were produced against recombinant CYP2A6 and proved to be very useful for immunoblotting and immunoinhibition studies. Availability of this expression system and specific antibodies should facilitate characterization of the role of CYP2A6 in the metabolism of chemicals and in the study biological relevance of genetic polymorphisms of this enzyme.

References (51)

  • M. Sawada et al.

    Mutat. Res.

    (1998)
  • M.S. Dong et al.

    Arch. Biochem. Biophys.

    (1996)
  • M.R. Waterman et al.

    Toxicol. Lett.

    (1995)
  • M. Oscarson et al.

    FEBS Lett.

    (1998)
  • S. Imaoka et al.

    Biochem. Pharmacol.

    (1996)
  • R.J. Duescher et al.

    Arch. Biochem. Biophys.

    (1994)
  • M.P. Pritchard et al.

    Arch. Biochem. Biophys.

    (1997)
  • T.A. van der Hoeven et al.

    J. Biol. Chem.

    (1974)
  • E.M.J. Gillam et al.

    Arch. Biochem. Biophys.

    (1993)
  • T. Omura et al.

    J. Biol. Chem.

    (1964)
  • P. Sandhu et al.

    Arch. Biochem. Biophys.

    (1993)
  • E.M.J. Gillam et al.

    Arch. Biochem. Biophys.

    (1994)
  • Y. Yasukochi et al.

    J. Biol. Chem.

    (1976)
  • R.A. Lubet et al.

    Arch. Biochem. Biophys.

    (1985)
  • W. Wray et al.

    Anal. Biochem.

    (1981)
  • P. Sandhu et al.

    Arch. Biochem. Biophys.

    (1994)
  • E.M.J. Gillam et al.

    Arch. Biochem. Biophys.

    (1995)
  • E.M.J. Gillam et al.

    Arch. Biochem. Biophys.

    (1995)
  • Z. Guo et al.

    Arch. Biochem. Biophys.

    (1994)
  • J. Kyte et al.

    J. Mol. Biol.

    (1982)
  • D.R. Nelson et al.

    Pharmacogenetics

    (1996)
  • F.P. Guengerich
  • S.E. Clarke

    Xenobiotica

    (1998)
  • S. Yamano et al.

    Biochemistry

    (1990)
  • J.S. Miles et al.

    Biochem. J.

    (1990)
  • Cited by (54)

    • Structural and functional effects of cytochrome b<inf>5</inf> interactions with human cytochrome P450 enzymes

      2017, Journal of Biological Chemistry
      Citation Excerpt :

      The influence of b5 on the major drug-metabolizing P450 enzyme CYP3A4 has been widely documented, with numerous CYP3A4-mediated reactions showing stimulation in the presence of both holo- and apo-b5 (21). CYP2A6 coumarin 7-hydroxylation has also been reported to be stimulated 1.5–2.5-fold by b5 (19, 22–24). CYP2D6 is a clinically significant P450 enzyme because of its ability to metabolize a wide array of pharmaceuticals and its high degree of polymorphism (25), but its metabolite production is reportedly less influenced by b5, at least with in vitro experiments (19, 20, 26, 27).

    • Cytochrome P450 is present in both ferrous and ferric forms in the resting state within intact Escherichia coli and hepatocytes

      2011, Journal of Biological Chemistry
      Citation Excerpt :

      Livers were obtained from male Sprague-Dawley rats (Central Animal Breeding Facility of the University of Queensland) under procedures approved by University of Queensland ethics committees, and microsomes were prepared as described previously (18). CYP1A2, CYP2A6, CYP2A13, CYP2C9, CYP2C19, CYP3A4, CYP176A1 (P450cin), and CYP101A1 were expressed in E. coli according to the general procedures outlined previously (19–24). Bacterial chaperones were coexpressed using the pGro7 plasmid to augment P450 yields (22, 25, 26).

    • Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5

      2011, Biochemical Pharmacology
      Citation Excerpt :

      Interestingly, both amino acid mutations (R139K and K399R) in the corresponding CYP2C8.3 protein are located on the proximal site of the heme in the binding region of cytochrome b5 and CPR [16] and may suggest an involvement of the redox-partners in the variable activity of CYP2C8. The activation of CYP enzymes by cytochrome b5 is well established [17] for CYP3A4 [18], CYP2B4 and variants [19], CYP2A6 [20], CYP2C9 [21] and CYP2C19 [22]. Further, cytochrome b5 is also reported to decrease reaction uncoupling [23] and increase kcat.

    View all citing articles on Scopus

    Supported by the Internal Grant Agency of Czech Ministry of Health, Grant IGA 3505-3 (1996-98), and the Grant Agency of Czech Republic, Grant 303/96/0373 (1996).

    2

    Fax: +420-2-6731 1236. E-mail: [email protected].

    View full text